Immunogenomic Correlates of Response to Cetuximab in Head and Neck Squamous Cell Carcinoma
Immune evasion is a sine qua non for cancer development. Mechanisms of resistance to immune modulating therapeutics in cancer are poorly understood. Less than 20% of patients with HNSCC have a lasting response to cetuximab. We hypothesized that acquired somatic alterations may provide a mechanism of immune evasion in cetuximab failure. Here, using a novel cohort of HNSCC patients treated with neoadjuvant cetuximab, we investigated mechanisms of immune escape from cetuximab therapy.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: D.L. Faden, F. Concha-Benavente, A. Bhaswanth Chakka, R.L. Ferris Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Carcinoma | Erbitux | Head and Neck Cancer | HNSCC | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Physics | Skin Cancer | Squamous Cell Carcinoma